Advertisement

Ovarian Cancer

ESM1 suppresses LncRNA GAS5/miR-23a-3p/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K/AKT pathway.

Mar 17, 2025

Cisplatin chemotherapy is an important treatment for advanced ovarian cancer (OC). However, the development of cisplatin resistance greatly limits the survival time of OC patients. Endothelial cell-sp...

Quiz Challenge – Who’s Most at Risk for Gynecologic Cancers?

Mar 12, 2025

Which of your patients are most at risk for developing cervical cancer, and where might distant metastases form? (function() { function getCookie(name) { var value = '; ' + document.cookie; va...

Financial Burden of Ovarian Cancer Care by Phase, Age, and Region

Feb 27, 2025

The following is a summary of “Cost of ovarian cancer by the phase of care in the United States,” published in the February 2025 issue of American Journal of Obstetrics & Gynecology by Adjei e...

Primary Cytoreductive Surgery Improves Survival in Stage IV Ovarian Cancer

Feb 19, 2025

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide populati...

Improved Survival With Primary Cytoreductive Surgery in Ovarian Cancer

Feb 07, 2025

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide populati...

Ultrasound Predicts Resectability in Tubo-Ovarian Cancer Comparable to CT and MRI

Dec 04, 2024

The following is a summary of “Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC s...

Prognostic Role of CD1a in OV and Recurrent OV Outcomes

Nov 20, 2024

The following is a summary of “CD1a affects the recurrence and prognosis of ovarian cancer,” published in the November 2024 issue of Obstetrics and Gynecology by Zhu et al.    Ovarian ca...

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.

Nov 04, 2024

In epithelial ovarian cancer (EOC), platinum resistance, potentially mediated by cancer stem cells (CSCs), often leads to relapse and treatment failure. Here, the role of spindle pole body component 2...

Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.

Oct 14, 2024

To determine the prognostic impact of microscopic residual disease after neoadjuvant chemotherapy (NACT) in patients undergoing interval debulking surgery (IDS) for advanced epithelial ovarian cancer ...

SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway.

Oct 14, 2024

Ovarian cancer caused the highest cancer-related mortality among female reproductive system malignancies. Platinum-based chemotherapy is still the footstone of the chemotherapy for ovarian cancer. How...

Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.

Sep 23, 2024

This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the trea...

Complex Expression Patterns of HDAC6 and ARID1A in Endometriosis Subtypes

Sep 20, 2024

The following is a summary of “Expression patterns of HDAC6 in correlation to ARID1A status in different subtypes of endometriosis: A retrospective tissue microarray analysis,” published in the Au...

Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.

Sep 09, 2024

Malignant ascites is commonly produced in advanced epithelial ovarian cancer (EOC) and serves as unique microenvironment for tumour cells. Acellular ascites fluid (AAF) is rich in signalling molecules...

MRG Prognostic Signature May Predict Survival Time of Patients With Ovarian Cancer

Aug 05, 2024

Ovarian cancer is a female-specific malignancy with high morbidity and mortality. The metabolic reprogramming of tumor cells is closely related to the biological behavior of tumors. The prognostic ...

Circular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer.

Jul 22, 2024

Cisplatin is integral to ovarian cancer treatment, yet resistance to this drug often results in adverse patient outcomes. The association of circular RNA (circRNA) with cisplatin resistance in ovarian...

Women With Endometriosis at Increased Risk for Ovarian Cancer

Jul 19, 2024

Women with endometriosis have an increased risk of ovarian cancer, with the highest risk seen for women with deep infiltrating endometriosis and/or ovarian endometriomas, according to a study publishe...

Prophylactic mesh to prevent incisional hernia in laparotomy for ovarian tumors.

Jun 24, 2024

Incisional hernias are a common complication of midline laparotomies. The aim of this study was to determine the impact of prophylactic mesh placement after midline laparotomy for ovarian tumors on th...

Batiraxcept-Paclitaxel Combination Shows Promise in High AXL-Expressing, Platinum-Resistant Ovarian Cancer

Jun 06, 2024

Results from the Phase 3 AXLerate-OC trial showed that the combination of batiraxcept and paclitaxel demonstrated a statistically significant improvement in progression-free survival (PFS) and overall...

Recent Insights into the Roles of PEST-Containing Nuclear Protein.

May 20, 2024

PEST-containing nuclear protein (PCNP), a short-lived small nuclear protein with 178 amino acids, is a nuclear protein containing two PEST sequences. PCNP is highly expressed in several malignant tumo...

miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.

May 06, 2024

Ovarian cancer is typically diagnosed at an advanced stage, recurs early and often, and currently lacks effective treatment. Therefore, overall survival and progression-free survival are relatively sh...

SUBSPECIALTIES

Advertisement